Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LQDA NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia$71.21-8.6%$65.64$13.88▼$82.96$6.93B0.552.22 million shs2.17 million shsUTHRUnited Therapeutics$535.57-2.1%$555.98$272.12▼$609.35$23.22B0.58519,593 shs294,687 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia0.00%-1.27%+9.41%+100.59%+453.09%UTHRUnited Therapeutics0.00%-1.59%+0.20%-5.29%+85.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia$71.21-8.6%$65.64$13.88▼$82.96$6.93B0.552.22 million shs2.17 million shsUTHRUnited Therapeutics$535.57-2.1%$555.98$272.12▼$609.35$23.22B0.58519,593 shs294,687 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia0.00%-1.27%+9.41%+100.59%+453.09%UTHRUnited Therapeutics0.00%-1.59%+0.20%-5.29%+85.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLQDALiquidia 2.82Moderate Buy$68.88-3.28% DownsideUTHRUnited Therapeutics 2.83Moderate Buy$644.8220.40% UpsideCurrent Analyst Ratings BreakdownLatest UTHR and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026UTHRUnited Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$620.00 ➝ $613.007/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$701.00 ➝ $704.006/29/2026LQDALiquidia Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$64.00 ➝ $79.006/22/2026LQDALiquidia BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $109.006/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/5/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$67.00 ➝ $75.006/5/2026LQDALiquidia OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$75.006/5/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.006/4/2026LQDALiquidia Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$68.005/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $67.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLQDALiquidia$158.32M40.00N/AN/A$0.51 per share139.63UTHRUnited Therapeutics$3.18B7.14$32.30 per share16.58$164.81 per share3.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLQDALiquidia-$68.92M$0.14508.6814.47N/A7.74%46.82%7.06%8/11/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0919.7717.271.8040.62%19.24%17.25%7/29/2026 (Estimated)Latest UTHR and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2026Q2 2026UTHRUnited Therapeutics$7.07N/AN/AN/A$805.22 millionN/A5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLQDALiquidiaN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLQDALiquidia1.182.222.03UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLQDALiquidia64.54%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipLQDALiquidia25.60%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLQDALiquidia5088.93 million66.16 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableUTHR and LQDA HeadlinesRecent News About These CompaniesInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 SharesJuly 13 at 5:06 PM | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $52.56 Million Stock Holdings in United Therapeutics Corporation $UTHRJuly 13 at 4:56 AM | marketbeat.comUnited Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong ReturnsJuly 12 at 2:29 PM | finance.yahoo.comFifth Third Bancorp Raises Stock Holdings in United Therapeutics Corporation $UTHRJuly 12 at 11:19 AM | marketbeat.comUnited Therapeutics (UTHR) Following FDA Approval Is The Stock Fully ValuedJuly 11 at 6:29 PM | finance.yahoo.comBank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)July 11 at 1:22 PM | theglobeandmail.comJan Malcolm Sells 325 Shares of United Therapeutics (NASDAQ:UTHR) StockJuly 11 at 10:21 AM | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) Price Target Lowered to $613.00 at Bank of AmericaJuly 11 at 10:05 AM | americanbankingnews.comCandriam S.C.A. Reduces Position in United Therapeutics Corporation $UTHRJuly 11 at 9:19 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 325 Shares of StockJuly 10 at 5:06 PM | marketbeat.comBank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $613.00July 10 at 2:11 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $5,255,115.00 in StockJuly 10 at 5:51 AM | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 SharesJuly 9, 2026 | marketbeat.comUnited Therapeutics Stock Rises 14% YTD: Here's What You Need to KnowJuly 9, 2026 | zacks.comIs United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation?July 8, 2026 | insidermonkey.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockJuly 8, 2026 | insidertrades.comUnited Therapeutics acquires Massachusetts biotech companyJuly 7, 2026 | ncbiotech.orgNUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $704.00July 7, 2026 | marketbeat.comUnited Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling BuyJuly 6, 2026 | seekingalpha.comUnited Therapeutics Vs. Regencell Bioscience: I Choose Profits Over PromisesJuly 6, 2026 | seekingalpha.comHsbc Holdings PLC Sells 12,743 Shares of United Therapeutics Corporation $UTHRJuly 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR and LQDA Company DescriptionsLiquidia NASDAQ:LQDA$71.21 -6.72 (-8.62%) Closing price 04:00 PM EasternExtended Trading$74.25 +3.04 (+4.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.United Therapeutics NASDAQ:UTHR$535.57 -11.49 (-2.10%) Closing price 04:00 PM EasternExtended Trading$531.77 -3.80 (-0.71%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
